April 23, 2014 8:50 PM ET


Company Overview of Pamlab, L.L.C.

Company Overview

Pamlab, L.L.C., a biomedical company, provides research and development and production services for prescription medical foods to health care providers to address the nutritional requirements of their patients. Its products include Metanx, an orally administered medical food for the dietary management of endothelial dysfunction in patients with diabetic peripheral neuropathy; Deplin, an orally administered medical food for the dietary management of suboptimal folate levels in depressed patients or hyperhomocysteinemia in schizophrenia patients; Neevo and NeevoDHA, which are for the dietary management of impaired metabolic processes in women who face high to intermediate risk pregnancies and ...

4099 Highway 190 East Service

Covington, LA 70433-4941

United States

Founded in 1957





Key Executives for Pamlab, L.L.C.

Chief Executive Officer
Age: 51
Senior Vice President of Finance
Chief Operations Officer
President of Red River Pharma
Compensation as of Fiscal Year 2013.

Pamlab, L.L.C. Key Developments

Pamlab, L.L.C. and Breckenridge Pharmaceutical, Inc. Announce Joint Venture to Provide Authorized Generics on Pamlab Branded Medical Food Products

Pamlab, L.L.C. and Breckenridge Pharmaceutical, Inc. have entered into a joint venture for the marketing and distribution of authorized generic versions of Pamlab's medical food products containing Metafolin(R). Breckenridge expects to launch the first of these products on October 1, 2012. The joint venture includes a sub-license from Pamlab to Breckenridge for exclusive patents applicable to Pamlab's popular medical foods such as Metanx(R), Deplin(R) and CerefolinNAC(R).

Pamlab, L.L.C.'s Study Indicates Alleviation in Diabetes-Induced Large and Small Fiber Neuropathies in Rats with Prescription Medical Food

Pamlab, L.L.C. announced that a study, which demonstrated that dietary management of endothelial dysfunction with Metanx(R) alleviates diabetes-induced large and small fiber neuropathies in rats, was published in the journal Diabetes. The study, conducted by Dr. Irina G. Obrosova and her colleagues from Pennington Biomedical Research Center, utilized Zucker diabetic fatty (ZDF) rats, a model of Type 2 diabetes, to evaluate Metanx(R) on diabetic neuropathy. The study also demonstrated that nutritional management of diabetic peripheral neuropathy with Metanx(R) increased intraepidermal nerve fiber density i.e., promoted small sensory nerve fiber regeneration in the test rats. Diabetic neuropathy is caused by disruption in the natural metabolic processes in blood vessels and peripheral nerve tissues, a common complication of diabetes. In the study, ZDF rats displayed peripheral nerve oxidative stress and diabetic peripheral neuropathy symptoms such as nerve conduction velocity deficit, small sensory fiber dysfunction, and intraepidermal nerve fiber loss. Metanx(R), a medical food, alleviated diabetes-associated sensory nerve conduction velocity deficit and small sensory nerve fiber neuropathy at a body-weight equivalent of human dose. Also, unlike many other experimental therapeutics tested thus far, Metanx(R) induced small sensory fiber regeneration in the rats, potentially due to abrogation of non-enzymatic glycation and oxidative stress.

Similar Private Companies By Industry

Company Name Region
Endo Health Solutions Inc. United States
Envoy Therapeutics, Inc. United States
Perlan Therapeutics, Inc. United States
OncoSource Rx, LLC United States
Ethos Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Pamlab, L.L.C., please visit www.pamlab.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.